{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-049896","form_type":"8-K","ticker":"KMTS","cik":"0001877184","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","filed_at":"2025-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.447646+00:00","generated_at":"2026-05-25T04:15:52.797480+00:00","sec_items":["1.01","3.03","5.03","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kestra Medical grants Kennedy Lewis and Perceptive warrants for 434,916 shares; adopts 2025 equity plan","bullets":["Issued three warrants to Kennedy Lewis Capital Partners and Perceptive Credit Holdings to purchase 434,916 common shares at $17.81 per share, exercisable until Dec 28, 2030.","Warrants replace a prior warrant to Kennedy Lewis and are subject to a 180-day lock-up from March 7, 2025.","Adopted the 2025 Omnibus Incentive Plan, authorizing grants of options, RSUs, and other share-based awards to employees, officers, and directors.","Increased authorized share capital to $100M, divided into 100M common shares; ordinary shares redesignated as common shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-049896","json":"https://secwatch.observer/filing/0001193125-25-049896.json","markdown":"https://secwatch.observer/filing/0001193125-25-049896.md","text":"https://secwatch.observer/filing/0001193125-25-049896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1877184/000119312525049896/0001193125-25-049896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1877184/000119312525049896/d890644d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T04:15:52.797480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26d80bcd3b879c6419f157bddfdf36ba9bada854","claim":"KESTRA MEDICAL TECHNOLOGIES, LTD.: The company's Amended and Restated bye-laws became effective (effective 2025-03-07).","evidence_excerpt":"On March 7, 2025, the Company’s Amended and Restated bye-laws (the “ bye-laws ”), in the form previously filed as Exhibit 3.3 to the Registration Statement, became effective.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1877184/000119312525049896/0001193125-25-049896-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-03-07"}],"fact_type":"governance_change"},{"claim_id":"4cd1bac49e51f39c45acf6e9e38c973c92ad10ff","claim":"KESTRA MEDICAL TECHNOLOGIES, LTD.: The company increased authorized share capital to US$100,000,000 divided into 100,000,000 common shares and redesignated ordinary shares as common shares (effective 2025-03-07).","evidence_excerpt":"As previously disclosed in the Registration Statement, in connection with the Offering, the Company’s Board of Directors and its sole shareholder approved, among other things, an increase to the Company’s authorized share capital to US$100,000,000 divided into 100,000,000 common shares of par value of US$1.00 each and a redesignation of the Company’s authorized and issued ordinary shares as common shares.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1877184/000119312525049896/0001193125-25-049896-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-03-07"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}